anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Junctional ectopic tachycardia (JET) is a serious tachyarrhythmia following pediatric cardiac surgery. It isn't easy to treat and better to be prevented. This study aimed to examine the prophylactic effects of dexmedetomidine, MgSO4, or their combination in reducing JET following pediatric open cardiac surgery.
METHODS: Hundred and twenty children under 5 years, weighing more than 5 kg, who were scheduled for corrective acyanotic cardiac surgeries were randomized into three groups. Group MD (Dexmedetomidine-MgSO4 group): received dexmedetomidine 0.5 μg/kg IV over 20 min after induction, then infusion 0.5 μg/kg/h for 72 h, and 50 mg/kg bolus of MgSO4 with aortic cross-clamp release, then continued administration for 72 h postoperatively at a dose of 30 mg/kg/day. Group D (the dexmedetomidine group) received the same dexmedetomidine as the MD group in addition to normal saline instead of MgSO4. Group C (control group): received normal saline instead of dexmedetomidine and MgSO4. The primary outcome was the detection of JET incidence; the secondary outcomes were hemodynamic parameters, ionized Mg, vasoactive-inotropic score, extubation time, PCCU and hospital stay, and perioperative complications.
RESULTS: The incidence of JET was significantly reduced in Group MD and Group D (p = .007) compared to Group C. Ionized Mg was significantly higher in Group MD than in Groups D and C during rewarming and in the ICU (p < .001). Better hemodynamic profile in Group MD compared to Group D and Group C throughout surgery and in the ICU, the predictive indexes were significantly better in Group MD than in Groups D and C (p < .001). Including the extubation time, PCCU, and hospital stay.
CONCLUSION: Dexmedetomidine alone or combined with MgSO4 had a therapeutic role in the prevention of JET in children after congenital heart surgery.
Interleukin-6 (IL-6) and hypoxia-inducible factor-1α (HIF-1α) play important roles in epithelial-mesenchymal transformation (EMT) and tumor development. Previous studies have demonstrated that IL-6 promotes EMT, invasion, and metastasis in epithelial ovarian cancer (EOC) cells by activating the STAT3/HIF-1α pathway. MicroRNA (miRNA) is non-coding small RNAs that also play an important role in tumor development. Notably, Let-7 and miR-200 families are prominently altered in EOC. However, whether IL-6 regulates the expression of Let-7 and miR-200 families through the STAT3/HIF-1α signaling to induce EMT in EOC remains poorly understood. In this study, we conducted in vitro and in vivo investigations using two EOC cell lines, SKOV3, and OVCAR3 cells. Our findings demonstrate that IL-6 down-regulates the mRNA levels of Let-7c and miR-200c while up-regulating their target genes HMGA2 and ZEB1 through the STAT3/HIF-1α signaling in EOC cells and in vivo. Additionally, to explore the regulatory role of HIF-1α on miRNAs, both exogenous HIF blockers YC-1 and endogenous high expression or inhibition of HIF-1α can be utilized. Both approaches can confirm that the downstream molecule HIF-1α inhibits the expression and function of Let-7c and miR-200c. Further mechanistic research revealed that the overexpression of Let-7c or miR-200c can reverse the malignant evolution of EOC cells induced by IL-6, including EMT, invasion, and metastasis. Consequently, our results suggest that IL-6 regulates the expression of Let-7c and miR-200c through the STAT3/HIF-1α pathway, thereby promoting EMT, invasion, and metastasis in EOC cells.
PURPOSE: A pharmaceutical composition containing quinolone alkaloid compounds derived from Evodia fructus for preventing and treating inflammatory diseases or infectious diseases is provided to suppress binding between ICAM-1 and LFA-1(CD11a/CD18). CONSTITUTION: A composition for preventing or treating common cold contains Evodia fructus extract, fraction thereof, or compound of chemical formula 1-4. An external use skin formulation contains the composition. The external use skin formulation is used in the form of ointments, lotions, sprays, patchs, creams, powders, suspensions, or gels. A food product contains the composition. A pharmaceutical composition for preventing or treating inflammatory diseases or infectious diseases contains a compound of chemical formula 3 or 4 as an active ingredient. The compound of chemical formula 3 or 4 is isolated from Evodia fructus.
BACKGROUND: Although hinged prostheses have been used successfully in complex revision total knee arthroplasty (TKA), concerns exist regarding early failure due to aseptic loosening and other mechanical complications. The use of metaphyseal cones and hybrid cement fixation have been studied in unlinked constrained primary or revision TKA, but their impact on the survivorship of hinged prostheses has yet to be investigated.
METHODS: We identified a consecutive series of 164 hinged prostheses and collected data on demographics, indications, complications, and re-revisions in patients who had fully cemented versus hybrid stems, with and without metaphyseal cones. A multivariate analysis was performed to identify independent variables associated with re-revision as the primary end point.
RESULTS: In total, 84 patients (51.2%) had fully cemented stems, and 80 patients (48.8%) had hybrid stems. Cones were used in 73 patients (44.5%). At a mean follow-up of 3.4 ± 2.2 years, 42 patients underwent re-revision (25.8%), most commonly for infection (12.2%), followed by loosening (6.7%) and periprosthetic fracture (3.7%). Patients who had fully cemented stems had lower re-revision rates than hybrid fixation constructs (19 versus 26%, P = .043). Using multivariable regression, a construct with hybrid fixation with cones (odds ratio = 2.39; P = .037) was an independent risk factor for failure. Utilization of cones alone did not have an effect on re-revision rates at 3.4-year follow-up.
CONCLUSIONS: While we found no difference with the use of cones, patients undergoing revision TKA with a hinge prosthesis and fully cemented stems had better overall survivorship than hybrid stems.
FIELD: food industry, more particularly, dietic and prophylactic food products, and also perfume-cosmetic and pharmaceutical industries. SUBSTANCE: biologically active additive comprises concentrate of chlorophyll derivatives, adaptogen and/or detoxicant as macro-and microelements, and accompanying agents wherein chlorophyll derivatives account for 33.000 mg%, accompanying agents carotinoids up to 1500 mg%, vitamin E up to 360 mg% and fatty acids up to 30%. Biologically active additive further comprises vegetable and animal raw material. This makes it possible to prepare additive which has optimally balanced components and possesses antiseptic adaptogenic and/or detoxifying properties. EFFECT: improved properties of the additive. 17 cl, 5 ex
The invention discloses an extract of the effective fractions of two Chinese herbal medicines (smilax macrophylla Ver. and smilax trinervula Miq.) in smilax for treatment of acute gouty arthritis, and extraction methods thereof. The extract of effective fractions are prepared by the following methods of: crushing the smilax macrophylla Ver. or the smilax trinervula Miq., extracting by decocting in water, collecting the water decoction, and filtering to obtain the extract; or crushing the smilax macrophylla Ver. or the smilax trinervula Miq., extracting by using 10-90% ethanol, collecting the ethanol extract, and recovery the ethanol to obtain the extract. The effective fractions not only can release the inflammation response of redness, swelling, heat, and aching of joints in acute phase, but also can reduce the uric acid level in blood aiming at the pathogenesis; and because the effective fractions has the effect of simultaneous treatment of principal and subordinate symptoms of gout, safe and reliable medicines with good curative effect for treatment of acute gouty arthritis can be prepared by using the effective fractions. The extraction technology for the effective fractions of the invention is simple, safe, easy to operate and low in cost, without the need of high temperature, high pressure or special equipment.
This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
This systematic review aims to identify the sleep parameters of Olympic athletes and the instruments used to assess and monitor the sleep of these athletes. The search was conducted until February 2023 and was performed in PubMed, Web of Science, and Scopus databases. This systematic review has included studies that investigated at least one of the following sleep parameters: total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), awakenings after sleep onset (WASO), quality of sleep, daytime sleepiness, and chronotype; the participants were Olympic athletes. The search returned a total of 280 studies. After screening based on exclusion and inclusion criteria, 11 studies were included. The main results demonstrate that Olympic athletes have TST of 06:10 h, SE of 84%, SOL of 28 min, and WASO of 49 min. The most predominant chronotype is indifferent; over half of the athletes have poor sleep quality and complaints. Furthermore, actigraphy was the most used method to assess sleep. It is concluded that Olympic athletes have TST, SE, and WASO poor than the recommended values. In addition, sleep complaints and poor sleep quality were also observed. Among the objective sleep assessment methods, actigraphy was the method most frequently used in this population.
Participants in the experimental group received a weekly 1-hour musical training lesson for 6 months delivered by professionally qualified musicians. The participants will be assigned a particular musical instrument to learn, and this is based on their interests as well as their capabilities (i.e., fine motor skills), The training will begin at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song).
AIM: For patients who present to the emergency departments (ED) with undifferentiated chest pain, the risk of major adverse cardiac events (MACE) may be underestimated in low-HEART score patients. We aimed to identify characteristics of patients who were classified as low risk by HEART score but subsequently developed MACE at 6 weeks.
METHODS: We studied a multiethnic cohort of patients who presented with chest pain arousing suspicion of acute coronary syndrome to EDs in the Netherlands and Singapore. Patients were risk-stratified using HEART score and followed up for MACE at 6 weeks. Risk factors of developing MACE despite low HEART scores (scores 0-3) were identified using logistic and Cox regression models.
RESULTS: Among 1376 (39.8%) patients with low HEART scores, 63 (4.6%) developed MACE at 6 weeks. More males (53/806, 6.6%) than females (10/570, 2.8%) with low HEART score developed MACE. There was no difference in outcomes between ethnic groups. Among low-HEART score patients with 2 points for history, 21% developed MACE. Among low-HEART score patients with 1 point for troponin, 50% developed MACE, while 100% of those with 2 points for troponin developed MACE. After adjusting for HEART score and potential confounders, male sex was independently associated with increased odds (OR 4.12, 95%CI 2.14-8.78) and hazards (HR 3.93, 95%CI 1.98-7.79) of developing MACE despite low HEART score.
CONCLUSION: Male sex, highly suspicious history and elevated troponin were disproportionately associated with MACE. These characteristics should prompt clinicians to consider further investigation before discharge.
Multiple-participant cohorts of \>= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, every-2-weeks (Q2W), or once-a-week (QW) dosing regimens, respectively to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Additionally, step-up dosing regimens with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
Oral sustained release opioid formulation comprises: an opioid analgesic, a retardant material to cause the opioid analgesic to be released at a rate to provide an analgesic effect after oral admin. to a human patient for 24 hrs, the formulation when administered in humans providing an initially rapid rate of rise in the plasma conc. of the opioid characterised by providing an absorption half-life of 1-8 hrs. in the fastened state. Method for titrating human patients with a sustained release oral opioid formulation comprises: 1) administering to a human patient on a once-a-day basis a unit dose of an oral sustained release formulation comprising a dose of an opioid analgesic and a retardant material as described above, 2) monitoring pharmacokinetic and pharmacodynamic parameters elicited by the formulation in the human patient and determining whether the pharmacokinetic and/or pharmacodynamic  parameters are appropriate to treat the patient on a repeated basis, 3) titrating t he patient by adjusting the dose of the opioid analgesic administered to the patient by administering a unit dose of the sustained release opioid analgesic formulation if it is determined that the pharmacokinetic and/or the pharmacodynamic parameters are not satisfactory or maintaining the dose of the opioid analgesic in the unit dose at a previously administered amt. if the pharmacokinetic and/or pharmacodynamic parameters are deemed appropriate, 4) continuing the step 3 titration by adjusting the dose of the opioid analgesic until appropriate steady state pharmacokinetic and/or pharmacodynamic parameters are achieved in the patient, and 5) continuing the admin. of the dose of the opioid analgesic in the oral sustained release formulation on a once-a-day basis until treatment is terminated.
This is an open-label (all people know the identity of the intervention), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the anti-tumor activities and safety of abiraterone acetate in participants with cancer who have failed taxane (docetaxel)-based chemotherapy. Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally (by mouth), once daily after an overnight fast until disease progression, lack of disease response after six 28-day cycles of treatment, or when unacceptable toxicity is encountered. Participants will be treated for up to 12 cycles. All participants will receive a concurrent low-dose glucocorticoid (such as prednisone 5 mg tablet twice daily/prednisolone 0.5 mg tablet once daily). Treatment will be continued in responding participants until death, or disease progression, or end of the study (which is Week 148). Efficacy will primarily be assessed through prostate specific antigen response according to Prostate Specific Antigen Working Group (PSAWG) criteria. Participants' safety will be monitored throughout the study. Participants who have completed 12 cycles of abiraterone acetate treatment, and continue to receive clinical benefit from such treatment, will be eligible to enter the extension study. Participants who enter the extension study will continue taking abiraterone acetate at the dose they were receiving at the end of the main study together with low-dose glucocorticoid. Efficacy and safety will be monitored throughout the extension study. Study treatment will end when the patient dies, is lost to follow-up, withdraws informed consent, experiences sustained side-effects, has disease progression, or the sponsor discontinues the extension study. After the end of study visit is completed for the extension study, participants will be followed every 12 weeks for survival for up to 3 years following entry into the extension study.
FIELD: veterinary medicine. SUBSTANCE: 10% solution of concentrated herbal lucerne extraction is applied. Postoperative wound is treated by its rinsing with the solution through a syringe immediately after the floor of the auricle having been cut short. Suture material is soaked with the same solution. In the following days the wound surface is to be drained with cotton wool or gauze napkins wetted with the above mentioned solution. EFFECT: accelerated healing of wounds.
PROBLEM TO BE SOLVED: To obtain the subject agent that can inhibit the steep increase of blood sugar level after the meal to reduce the load on the pancreatic β-cells, can be utilized in the dietary therapy for patients with insulin-independent diabetes and can reduce the absorption of blood sugar after loading of glucose by using Cirsium martimum Makino and/or its extract. SOLUTION: The objective blood sugar increase suppressor comprises Cirsium maritimum Makino and/or its extract. The active ingredient is preferably cirsimarin represented by the formula. The extract is obtained by using water, ethanol or the like as a solvent. The deily dose of this hypoglyemic agent is >=1.0 g/kg body weight as the dried solid of the plant, while the dose is >=10 mg/kg body weight in the case of the extract. This inhibitor is given to the patients in the preparation form of a liquid dispersion, a soft extract or the like, further excipient, adjuvant and the like may be admixed into powder, granules and the like.
Subjects attend one single visit. If needed, COPD subjects are asked to stop any respiratory related medication such as short and long acting bronchodilators 72 hours prior to the visit. Subjects are asked to arrive early in the morning. After informed consent and appropriate screening of medical history, all subjects complete the mMRC scale. A complete medical history is collected. Subjects thereafter complete pulmonary function testing pre- and 30-min post-bronchodilator. Subjects are given a normal mixed meal and are asked not to drink alcohol or coffee.

A symptom-limited incremental cycle exercise test is performed on the same day, at least 6 hours after the bronchodilator test and at least 4 hours after the meal. After a steady-state resting period, a 3-min warm-up is conducted at about 20% of individually estimated maximal work load (Wmax), and the load is increased every minute in such a way that the test duration is \>8 and \<12 min. The following data are obtained breath by breath and expressed as 30-s averages: V'O2 and carbon dioxide production (V'CO2); minute ventilation (V'E); tidal volume (VT); respiratory rate; and ventilatory equivalents for oxygen and carbon dioxide. Blood pressure is measured every minute by a sphygmomanometer. Blood samples are withdrawn from the arterialized earlobe at rest and at near-maximal exercise. Tests are terminated at the point of symptom limitation (peak exercise). Upon exercise cessation, subjects are asked to verbalize their main reason for stopping exercise (breathing discomfort, leg discomfort or both).
PURPOSE:To obtain the titled protein having the stabilizing action on a proteinic solution, e.g. casein or erythrocytes, etc. at room temperature, by adding acetone to a solution containing an alpha1-acidic glycoprotein obtained from a blood plasma. CONSTITUTION:Acetone of 4.5-8pH in >=35% concentration is added to a solution containing an alpha1-acidic glycoprotein (AGP) obtained from a blood plasma. The resultant mixture is then allowed to stand at room temperature for 15min- 2hr to deposit the AGP fully. The formed precipitate is then separated by the ultracentrifugation, filtration, etc. If the purity of the separated precipitate is high, the precipitate is dried by the vacuum drying, etc. to give the AGP product. The blood plasma may be not only the human blood plasma but also the blood plasma of an animal, e.g. a rabbit, horse, sheep, pig, etc.
Warfarin sodium is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age ≥65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS) and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2CP and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY: Metabolism and DOSAGE AND ADMINISTRATION). Bleeding is more likely to occur during the starting period and with a higher dose of warfarin sodium (resulting in a higher INR).

Intramuscular (I.M.) injections of concomitant medications should be confined to the upper extremities which permits easy access for manual compression, inspections for bleeding and use of pressure bandages.

Caution should be observed when warfarin sodium tablets are administered concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, to be certain that no change in anticoagulation dosage is required. In addition to specific drug interactions that might affect PT/INR, NSAIDs, including aspirin, can inhibit platelet aggregation, and can cause gastrointestinal bleeding, peptic ulceration and/or perforation.
Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
The study is an evaluation of a new approach to treating Anorexia Nervosa (F.50.0 and F 50.1) called Family-based and Metacognitive therapy. The treatment integrates both family-based work approach, where the parents learn to be in control of the meal situation and communicate better with their child. The metacognitive treatment approach, is targeting the child to work with its problems with emotional regulation and self-esteem issues, but also their attitudes to body and weight. Our aim is to both address what the overall effect of the treatment will be, but also to test if an active follow-up after discharge will lead to reduced relapse rates in the 12 months after treatment. We will apply the same approach to all included patients (A-B design), but the patients and their parents will be allocated to one of two different conditions for follow-up. The active follow-up involves receiving 3 sessions of metacognitive therapy, whereas the other group gets ordinary follow-up, with no sessions of MCT. All patients are assessed at baseline, pre-treatment, post-treatment, and by 6 and 12 months follow-up. The purpose of the design is to evaluate if the rate of relapse during the first year after discharge can be reduced